IgA tetramerization improves target breadth but not peak potency of functionality of anti-influenza virus broadly neutralizing antibody.
Animals
Antibodies, Neutralizing
/ immunology
Antibodies, Viral
/ immunology
Antiviral Agents
Cell Line
Chick Embryo
Dogs
Hemagglutinin Glycoproteins, Influenza Virus
/ immunology
Humans
Immunoglobulin A
/ immunology
Immunoglobulin A, Secretory
/ immunology
Influenza A virus
/ immunology
Influenza Vaccines
Influenza, Human
/ immunology
Madin Darby Canine Kidney Cells
Neutralization Tests
Orthomyxoviridae
/ immunology
Polymerization
Protein Binding
Recombinant Proteins
/ metabolism
Journal
PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
15
05
2018
accepted:
22
10
2018
entrez:
4
1
2019
pubmed:
4
1
2019
medline:
27
3
2019
Statut:
epublish
Résumé
Mucosal immunoglobulins comprise mainly secretory IgA antibodies (SIgAs), which are the major contributor to pathogen-specific immune responses in mucosal tissues. These SIgAs are highly heterogeneous in terms of their quaternary structure. A recent report shows that the polymerization status of SIgA defines their functionality in the human upper respiratory mucosa. Higher order polymerization of SIgA (i.e., tetramers) leads to a marked increase in neutralizing activity against influenza viruses. However, the precise molecular mechanisms underlying the effects of SIgA polymerization remain elusive. Here, we developed a method for generating recombinant tetrameric monoclonal SIgAs. We then compared the anti-viral activities of these tetrameric SIgAs, which possessed variable regions identical to that of a broadly neutralizing anti-influenza antibody F045-092 against influenza A viruses, with that of monomeric IgG or IgA. The tetrameric SIgA showed anti-viral inhibitory activity superior to that of other forms only when the antibody exhibits low-affinity binding to the target. By contrast, SIgA tetramerization did not substantially modify anti-viral activity against targets with high-affinity binding. Taken together, the data suggest that tetramerization of SIgA improved target breadth, but not peak potency of antiviral functions of the broadly neutralizing anti-influenza antibody. This phenomenon presumably represents one of the mechanisms by which SIgAs present in human respiratory mucosa prevent infection by antigen-drifted influenza viruses. Understanding the mechanisms involved in cross neutralization of viruses by SIgAs might facilitate the development of vaccine strategies against viral infection of mucosal tissues.
Identifiants
pubmed: 30605488
doi: 10.1371/journal.ppat.1007427
pii: PPATHOGENS-D-18-00987
pmc: PMC6317788
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Antiviral Agents
0
Hemagglutinin Glycoproteins, Influenza Virus
0
Immunoglobulin A
0
Immunoglobulin A, Secretory
0
Influenza Vaccines
0
Recombinant Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1007427Déclaration de conflit d'intérêts
National Institute of Infectious Diseases and Nippi, Inc. have filed patents regarding construction and use of tetrameric SIgA (application no. PCT/JP2015/070742). SS, TS, AA, YT, TU, KOG and HH are named as inventors on the application. YT, TU, and KOG are employees of Nippi, Inc.
Références
Methods Enzymol. 1985;116:37-75
pubmed: 3911017
Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6364-8
pubmed: 9177223
Appl Microbiol. 1969 Nov;18(5):824-33
pubmed: 4984203
Med Microbiol Immunol. 1975 Dec 30;162(1):9-14
pubmed: 1214709
J Biol Chem. 1999 Nov 19;274(47):33771-7
pubmed: 10559270
Emerg Microbes Infect. 2017 Dec 6;6(12):e110
pubmed: 29209053
Mol Immunol. 1997 Mar;34(4):323-31
pubmed: 9244345
J Immunol. 2010 Apr 1;184(7):3648-55
pubmed: 20208001
Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):3029-34
pubmed: 10077631
Nat Rev Immunol. 2012 Dec;12(12):821-32
pubmed: 23103985
J Virol. 2003 Apr;77(7):4095-103
pubmed: 12634368
J Virol. 2011 Nov;85(21):11048-57
pubmed: 21865387
Vaccine. 2017 Sep 18;35(39):5297-5302
pubmed: 28780981
AIDS. 2013 Jun 1;27(9):F13-20
pubmed: 23775002
mBio. 2017 Mar 21;8(2):
pubmed: 28325769
J Infect Dis. 2011 Dec 15;204(12):1879-85
pubmed: 21998477
mSphere. 2017 Dec 13;2(6):
pubmed: 29242836
J Immunol. 1996 Jul 1;157(1):156-9
pubmed: 8683109
Science. 2004 Mar 19;303(5665):1866-70
pubmed: 14764887
J Clin Microbiol. 1985 Aug;22(2):259-64
pubmed: 4031039
J Immunol Methods. 2015 Jul;422:102-10
pubmed: 25910833
Mucosal Immunol. 2017 Jan;10(1):228-237
pubmed: 27072605
Mucosal Immunol. 2009 Sep;2(5):412-26
pubmed: 19587640
PLoS Pathog. 2010 Mar 12;6(3):e1000801
pubmed: 20300659
Antiviral Res. 2014 Jul;107:76-83
pubmed: 24797696
Mucosal Immunol. 2008 Jan;1(1):11-22
pubmed: 19079156
J Exp Med. 1965 Jan 1;121:101-24
pubmed: 14253478
J Virol. 2004 Oct;78(20):11007-15
pubmed: 15452221
J Immunol. 1973 Dec;111(6):1653-60
pubmed: 4201552
J Immunol Methods. 2008 Jan 1;329(1-2):112-24
pubmed: 17996249
J Immunol. 2005 Nov 15;175(10):6694-701
pubmed: 16272325
Hum Vaccin Immunother. 2018 Jun 3;14(6):1351-1361
pubmed: 29425074
Viral Immunol. 2012 Oct;25(5):433-9
pubmed: 22985289
Mucosal Immunol. 2011 Nov;4(6):590-7
pubmed: 21937984
Nat Commun. 2014 Apr 10;5:3614
pubmed: 24717798
Cell Rep. 2018 Apr 3;23(1):90-99
pubmed: 29617676
PLoS One. 2014 Jan 17;9(1):e85582
pubmed: 24465606
Influenza Other Respir Viruses. 2016 Nov;10(6):518-524
pubmed: 27406695
Blood. 2012 Nov 29;120(23):4571-82
pubmed: 23065154
Infect Immun. 1985 Aug;49(2):459-62
pubmed: 2410367
Proc Natl Acad Sci U S A. 2015 Jun 23;112(25):7809-14
pubmed: 26056267
Vaccine. 2017 Sep 25;35(40):5388-5395
pubmed: 28866292
Mucosal Immunol. 2017 May;10(3):814-826
pubmed: 27966557
Hum Vaccin Immunother. 2013 Sep;9(9):1962-70
pubmed: 23896606